antibody drug conjugates
Everything filed under oncology in our medical research coverage, the 50 reports filed on it so far.
Medicare Part D premiums to jump 50% in 2027
Average monthly premiums for Medicare Part D prescription drug plans are projected to rise from $34 to $51 next year.
Flagship Pioneering launches AI drug discovery company Etcelera
Flagship Pioneering merged three AI biotech startups into a new company, Etcelera, on October 29, 2026. The firm, led by Adrian Rawcliffe, combines...
Setara Biosciences launches with $90 million for rare disease drug
A new biotech company, Setara Biosciences, has launched with $90 million to develop a therapy for Charcot-Marie-Tooth disease and overactive bladder...
Novo Nordisk lawsuit fails to halt Lilly obesity drug ads
A federal judge denied Novo Nordisk's request to block Eli Lilly's advertising campaign comparing weight-loss drugs Wegovy and Zepbound, finding no...
BioNTech's trastuzumab pamirtecan shows modest PFS benefit in HER2-low breast cancer
A Phase 3 trial for BioNTech and DualityBio's antibody-drug conjugate trastuzumab pamirtecan met its primary endpoint, delaying tumor progression in...
GSK and Ionis win first FDA approval for hepatitis B functional cure
The FDA has approved GSK and Ionis's RNA-based drug Hibsago, offering a functional cure for chronic hepatitis B in adults without cirrhosis after a...
FDA issues final guidance on prescription drug companion app labeling
The FDA has released final guidance clarifying when software used alongside prescription drugs must be included in a drug's official label and...
Arrowhead's ARO-MAPT shows major tau reduction in early trial
Arrowhead Pharmaceuticals' RNAi drug ARO-MAPT reduced tau protein by an average of 73% in healthy volunteers, demonstrating significant target...
ArriVent's furmonertinib fails key lung cancer trial endpoint
ArriVent BioPharma's oral lung cancer drug furmonertinib failed to significantly delay tumor progression versus chemotherapy in a late-stage study...
Regeneron and Sanofi Expand Antibody Alliance in $8 Billion Deal
Regeneron and Sanofi have expanded their long-standing collaboration with an $8 billion deal to co-develop four next-generation immunology drugs.
Amgen's Sjögren's drug succeeds in first Phase 3 trial
Amgen's experimental drug dazodalibep met its primary goal in a Phase 3 study for Sjögren's syndrome, showing early and sustained symptom improvement.
Novo Nordisk partners with Anthropic to accelerate drug discovery
Novo Nordisk has entered a collaboration with AI company Anthropic to speed up drug discovery and development.
FDA launches pilot to accelerate phase 1 trials
The FDA has opened a pilot program pairing drug sponsors with qualified research institutions to expedite IND reviews.
Cullinan and Taiho drug extends lung cancer progression-free survival
In a phase 3 trial, adding zipalertinib to chemotherapy improved median progression-free survival to 14.5 months, a six-month gain over chemo alone.
GSK's risvutatug rezetecan shows 18.5-month median overall survival
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for...
IL-33 Inhibitor Tozorakimab Cuts COPD Exacerbations
The biologic drug tozorakimab, which targets interleukin-33, significantly reduced the rate of moderate and severe exacerbations in patients with...
GLP-1 Drugs Linked to Fewer Asthma, COPD Attacks in Study
A large real-world study presented at the ERS Congress found patients with asthma or COPD who started a GLP-1 drug had a 14% lower risk of severe...
Roivant's lung hypertension drug hits Phase 2 goals
Roivant's mosliciguat reduced a key lung pressure measure by 56% in a Phase 2 trial for PH-ILD, with analysts citing multi-billion dollar potential.
Novartis Phase 3 Trial Fails for Lp(a) Drug Pelacarsen
Novartis's pelacarsen, an antisense drug developed with Ionis to lower lipoprotein(a), did not reduce major cardiovascular events in high-risk...
Novo Nordisk ends two more phase 3 trials
Novo Nordisk has discontinued two late-stage heart failure trials for its drug ziltivekimab after a data review.
Akeso's Ivonescimab Shows Lung Cancer Survival Edge
Akeso and Summit Therapeutics report their bispecific antibody ivonescimab helped lung cancer patients live longer than those on Merck's Keytruda.
Induced Proximity Therapies Gain Ground After First PROTAC Approval
The first FDA-approved PROTAC drug for breast cancer has validated a new class of medicines that work by bringing proteins together.
Novartis, Ionis heart drug fails in major Phase 3 trial
Novartis and Ionis Pharmaceuticals' experimental drug pelacarsen failed to reduce heart attacks, strokes or death in a Phase 3 study of over 8,000...
AbbVie's dual-acting myeloma drug etentamig meets Phase 3 endpoint
AbbVie reported that its bispecific antibody etentamig met the primary endpoint in a Phase 3 trial for multiple myeloma.